Change over period: —
NSE · NGLFINE
NGL FINE CHM
-17.6% from the 52-week high · +122.7% above the low
NGL Fine-Chem Ltd. manufactures pharmaceuticals and intermediates for usage in veterinary and human health. The company is headquartered in Mumbai, Maharashtra and currently employs 329 full-time employees. The firm caters to various global companies to custom manufacture pharmaceuticals. Its products include APIs Animal Health, APIs Human Health, Intermediates and Specialty Chemicals and Finished Dosage Form. The APIs Animal Health products include Homidium Chloride, Nitroxynil, Clorsulon, Parvaquone, Buparvaquone, Isometamidium Chloride Hydrochloride, Toldimfos Sodium, Butaphosphan, Imidocarb Dipropionate, Triclabendazole, Rafoxanide, Diminazene Aceturate, S-Methoprene, Carprofen, Flunixin Meglumine, and Imidocarb Dipropionate, among others. The APIs Human Health products include Nitazoxanide and Atovaquone. The Intermediates and Specialty Chemicals product includes 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-Ethyl Glucamine. The Finished Dosage Form products include Diminazene Aceturate Granules and Homidium Chloride Tablets.
The short version. NGL FINE CHM reported revenue of ₹159 crore for Sep 2026, up 32.5% from a year earlier. Net profit was ₹16 crore (up 60.0% year on year). Return on equity was 14.6% in Mar 2026. Promoter holding was 72.49% in Sep 2026, down 0.25 points over 8 quarters.
1 · The price
How has the stock traded?
NGL FINE CHM trades 17.6% below its 52-week high and 122.7% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹159 cr.
Sep 2026 net profit of ₹16 cr.
2.2 pts higher than a year earlier.
Revenue compounded at 22.1% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 159 | 139 | 149 | 128 | 120 | 104 | 95 | 89 |
| Net profit | 16 | 18 | 13 | 16 | 10 | 9 | 1 | 1 |
| Net margin % | 10.2 | 13.2 | 9.0 | 12.3 | 8.0 | 8.9 | 0.6 | 1.4 |
| EPS (₹) | 26.3 | 29.78 | 21.83 | 25.4 | 15.58 | 14.96 | 0.88 | 2.07 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|---|
| Revenue | 501 | 368 | 339 | 278 | 318 | 258 | 152 |
| Net profit | 48 | 21 | 41 | 20 | 50 | 57 | 8 |
| Net margin % | 9.6 | 5.7 | 12.2 | 7.4 | 15.7 | 22.0 | 5.5 |
| EPS (₹) | 77.9 | 34.19 | 66.88 | 33.18 | 80.77 | 91.81 | 13.49 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 14.6% in Mar 2026; debt to equity is 0.33.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 14.6 | 7.5 | 15.7 | 9.2 |
| Return on capital % | 17.2 | 9.6 | 20.7 | 12.5 |
| EBITDA margin % | 17.0 | 11.3 | 19.1 | 14.1 |
| Net margin % | 9.3 | 5.6 | 11.7 | 7.2 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 22.1% | 14.2% |
| Profit CAGR | 32.9% | -3.2% |
4 · The owners
Who holds it, and are they adding?
Down 0.25 pts over 8 quarters.
Unchanged over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 72.74 | 72.74 | 72.74 | 72.74 | 72.74 | 72.74 | 72.49 | 72.49 | -0.25 |
| FII | 0.04 | 0 | 0 | 0 | 0 | 0.03 | 0.05 | 0.04 | 0.0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0.02 | 0 | 0 |
| Public | 27.22 | 27.26 | 27.26 | 27.26 | 27.26 | 27.24 | 27.43 | 27.46 | +0.24 |
Mutual fund holdings · Oct 2026
2 schemes hold this stock
2 the month before.
- Motilal Oswal BSE Healthcare ETF0.03% of NAV
- Bandhan BSE Healthcare Index Fund0.03% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for NGL FINE CHM are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about NGL FINE CHM
What is the NGL FINE CHM share price?
NGL FINE CHM (NGLFINE) last closed at ₹2,807.50, down 1.44% on the day. Its 52-week range is ₹1,278.80 to ₹3,457.80.
What is the market cap of NGL FINE CHM?
NGL FINE CHM has a market capitalisation of about ₹1,763 crore. Its price-to-earnings ratio is 27.6.
How are NGL FINE CHM's latest results?
NGL FINE CHM reported revenue of ₹159 crore for Sep 2026, up 32.5% from a year earlier. Net profit was ₹16 crore (up 60.0% year on year). Return on equity was 14.6% in Mar 2026. Promoter holding was 72.49% in Sep 2026, down 0.25 points over 8 quarters.
Who owns NGL FINE CHM?
As of Sep 2026, shareholding was: Promoter 72.49%, FII 0.04%, Public 27.46%.
How many mutual funds hold NGL FINE CHM?
2 mutual fund schemes held NGL FINE CHM in October 2026. That compares with 2 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 12 Aug 2025 · Final Dividend - Rs. 1.75
- 16 Aug 2024 · Final Dividend - Rs. 1.75
- 18 Aug 2023 · Final Dividend - Rs. 1.75
- 22 Jun 2022 · Final Dividend - Rs. 1.75
- 12 Aug 2021 · Dividend - Rs. 1.75
- 06 Aug 2020 · Final Dividend - Rs. 1.75
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.